Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver crawled date : 2021 - 06 - 21 save search
DoorDash and Albertsons Companies Partner to Launch Unprecedented Access to On-Demand Grocery Delivery
Published: 2021-06-21 (Crawled : 15:15) - prnewswire.com
DASH 4 | $130.54 0.91% 92K
|
Retail Trade
|
| O: 0.1%
H: 5.97%
C: 3.41%
ACI | $20.32 25K
|
Retail Trade
|
| O: 0.67%
H: 2.65%
C: 2.19%
liver
CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2021
Published: 2021-06-21 (Crawled : 14:15) - biospace.com/
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 0.22%
H: 4.31%
C: 1.72%
positive liver
Akero Therapeutics Presents Analyses at the 2021 International Liver Congress
Published: 2021-06-21 (Crawled : 14:00) - biospace.com/
AKRO | $21.0 1.01% 1.09% 34
|
Health Technology
|
| O: 0.73%
H: 0.23%
C: -2.29%
liver presentation therapeutics
BlueCity's He Health to introduce online consultation services and expand PEP delivery network
Published: 2021-06-21 (Crawled : 13:00) - prnewswire.com
BLCT | $1.54 0.0%
|
Technology Services
|
| O: -0.14%
H: 0.86%
C: -0.86%
liver health
Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment with efruxifermin
Published: 2021-06-21 (Crawled : 13:00) - akerotx.com
AKRO | $21.0 1.01% 1.09% 34
|
Health Technology
|
| O: 0.73%
H: 0.23%
C: -2.29%
treatment fibrosis correlation liver efruxifermin
The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial
Published: 2021-06-21 (Crawled : 12:15) - akerotx.com
AKRO | $21.0 1.01% 1.09% 34
|
Health Technology
|
| O: 0.73%
H: 0.23%
C: -2.29%
treatment nash liver trial
Syneos Health Accelerates Decentralized Clinical Trial Delivery, Unveils New Collaboration with Site Sponsors
Published: 2021-06-21 (Crawled : 12:15) - globenewswire.com
SYNH | $42.98 0.0% 7.4M
|
Health Services
|
| O: 0.66%
H: 1.21%
C: 1.1%
collaboration liver trial health
Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH
Published: 2021-06-21 (Crawled : 12:00) - ir.akerotx.com
AKRO | $21.0 1.01% 1.09% 34
|
Health Technology
|
| O: 0.73%
H: 0.23%
C: -2.29%
fibrosis nash liver
Albireo Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming EASL International Liver Congress
Published: 2021-06-21 (Crawled : 11:00) - globenewswire.com
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 0.82%
H: 3.42%
C: 2.32%
phase 3 liver a3907
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021
Published: 2021-06-21 (Crawled : 11:00) - biospace.com/
GILD | $66.45 -0.87% 380K
|
Health Technology
|
| O: 0.57%
H: 0.86%
C: 0.54%
disease liver disease liver
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
CZOO | $9.98 100.0% 330K
|
AMST | $3.48 74.0% 21M
|
Technology Services
BOF | $1.78 52.14% 15M
|
CSSE 4 | $0.2184 43.4% 36M
|
Consumer Services
HKIT | $1.6 20.3% 160K
|
Technology Services
IMMP | $2.95 17.53% 260K
|
Health Technology
ACB | $7.32 16.56% 780K
|
Process Industries
HSCS | $0.1136 14.86% 17M
|
n/a
AEYE | $15.42 14.39% 150K
|
Technology Services
BACK | $3.75 13.64% 44K
|
Health Care and Social Assistan...
Your saved searches
Save your searches and get alerts when important news are released.